4,5-Dichlorothiophene-2-Carboxylic Acid CAS 31166-29-7 Assay >98.0% (GC) Rivaroxaban Impurity

Short Description:

4,5-Dichlorothiophene-2-Carboxylic Acid

CAS: 31166-29-7

Assay: >98.0% (GC)

Appearance: White Powder

High Quality, Commercial Production

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

31166-29-7 - Description:

Manufacturer Supply, High Purity, Commercial Production
Chemical Name: 4,5-Dichlorothiophene-2-Carboxylic Acid
CAS: 31166-29-7

31166-29-7 - Chemical Properties:

Chemical Name	4,5-Dichlorothiophene-2-Carboxylic Acid
Synonyms	Rivaroxaban Impurity P; Rivaroxaban Related Impurity 1
CAS Number	31166-29-7
Stock Status	In Stock
Molecular Formula	C5H2Cl2O2S
Molecular Weight	197.04
Melting Point	196.0~197.0℃
Density	1.708±0.06 g/cm3
Storage Condition	Under Inert Gas (Nitrogen or Argon) at 2~8℃
COA & MSDS	Available
Place of Origin	Shanghai, China
Brand	Ruifu Chemical

31166-29-7 - Specifications:

Item	Specifications
Appearance	White Powder
Assay / Analysis Method	>98.0% (GC)
Identification	NMR, LCMS
Loss on Drying	≤1.00%
Total Impurities	<2.00%
Test Standard	Enterprise Standard
Usage	Rivaroxaban (CAS 366789-02-8) Related Impurity

Package & Storage:

Package: Bottle, Aluminium foil bag, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

31166-29-7 - Risk and Safety:

Risk Codes R36/37/38 - Irritating to eyes, respiratory system and skin.
R20/22 - Harmful by inhalation and if swallowed.
Safety Description S20 - When using, do not eat or drink.
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S35 - This material and its container must be disposed of in a safe way.
HS Code 2934999099

31166-29-7 - Application:

4,5-Dichlorothiophene-2-Carboxylic Acid (CAS: 31166-29-7) is a Rivaroxaban (CAS 366789-02-8) Related Impurity. It is used in the preparation of compounds that have therapeutic BACE1 and BACE2 inhibitors which are used for the treatment of Alzheimer’s disease, type 2 diabetes and other metabolic disorders.